Fluorinated estrogen receptor modulators and uses thereof

作者: Andiliy G. Lai , Nicholas D. Smith , Celine Bonnefous , Steven P. Govek , Mehmet Kahraman

DOI:

关键词:

摘要: Described herein are compounds that estrogen receptor modulators. Also described pharmaceutical compositions and medicaments include the herein, as well methods of using such modulators, alone in combination with other compounds, for treating diseases or conditions mediated dependent upon receptors.

参考文章(124)
Anette Sommer, Jens Hoffmann, Daniel Korr, Jan Kunde, Use of fibroblast growth factor 7 (fgf7) and of the receptor fgfr2b as biomarkers ,(2008)
Hermann Kuenzer, Ludwig Zorn, Karl-Heinrich Fritzemeier, Uwe Kollenkirchen, Christa Hegele-Hartung, Rolf Jautelat, 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity ,(2001)
David Duane Pfizer Global R. D. Thompson, Andrew George Pfizer Global R. D. Lee, Wesley Warren Pfizer Global R. D. Day, Use of estrogen agonists / antagonists for the treatment of sexual dysfunction ,(2001)
Peter J. Kushner, Weijun Feng, Brian L. West, Keith R. Yamamoto, Robert J. Fletterick, Beatrice Darimont, Richard L. Wagner, John D. Baxter, Methods for modulating nuclear receptor coactivator binding ,(1999)
Eugene Anthony Terefenko, Richard Craig Winneker, Gary S. Grubb, Puwen Zhang, Diane Deborah Harrison, Jeffrey Curtis Kern, Andrew Fensome, Use of cyclothiocarbamate derivatives in treatment of hormone-related conditions ,(2003)
Robert Louis Pfizer Global Res. Devel. Rosati, Use of an estrogen agonist/antagonist for treating cataracts ,(2001)
Christian Hansen, Henrik Nilsson, Stephan Christgau, Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions ,(2004)